FR3101538B1 - Composition of the physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells. - Google Patents

Composition of the physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells. Download PDF

Info

Publication number
FR3101538B1
FR3101538B1 FR1911117A FR1911117A FR3101538B1 FR 3101538 B1 FR3101538 B1 FR 3101538B1 FR 1911117 A FR1911117 A FR 1911117A FR 1911117 A FR1911117 A FR 1911117A FR 3101538 B1 FR3101538 B1 FR 3101538B1
Authority
FR
France
Prior art keywords
glutamine
usable
physiological solution
composition
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1911117A
Other languages
French (fr)
Other versions
FR3101538A1 (en
Inventor
Bruno Eto
Bernard Gressier
Cédric Renéville
Thierry Schmitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Action Vitale
Original Assignee
Action Vitale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Action Vitale filed Critical Action Vitale
Priority to FR1911117A priority Critical patent/FR3101538B1/en
Publication of FR3101538A1 publication Critical patent/FR3101538A1/en
Application granted granted Critical
Publication of FR3101538B1 publication Critical patent/FR3101538B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition de la solution physiologique contenant de l’eau de mer et de la glutamine et utilisable pour augmenter la viabilité fonctionnelle des tissus biologiques et des cellules vivantes. Selon l'invention, cette solution physiologique dite de Renéville permet également d’étudier le passage intestinal des médicaments, des nutriments, de vitamines et des xénobiotiques à longue libérationComposition of the physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells. According to the invention, this so-called Renéville physiological solution also makes it possible to study the intestinal passage of drugs, nutrients, vitamins and long-release xenobiotics.

FR1911117A 2019-10-07 2019-10-07 Composition of the physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells. Active FR3101538B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR1911117A FR3101538B1 (en) 2019-10-07 2019-10-07 Composition of the physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1911117A FR3101538B1 (en) 2019-10-07 2019-10-07 Composition of the physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells.
FR1911117 2019-10-07

Publications (2)

Publication Number Publication Date
FR3101538A1 FR3101538A1 (en) 2021-04-09
FR3101538B1 true FR3101538B1 (en) 2023-05-05

Family

ID=69743312

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1911117A Active FR3101538B1 (en) 2019-10-07 2019-10-07 Composition of the physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells.

Country Status (1)

Country Link
FR (1) FR3101538B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005033809A1 (en) * 2005-07-20 2007-01-25 Kohler, Peter Composition, useful for activating growth hormones and strengthening the immune system, comprises amino acids and isotonic saline
FR3040860B1 (en) * 2015-09-10 2020-05-15 Universite de Bordeaux INJECTABLE STORAGE MEDIUM FOR STORAGE OF PLACENTAL BLOOD, BONE MARROW AND PERIPHERAL BLOOD CELLS
FR3041253B1 (en) * 2015-09-21 2019-05-24 Fabienne Bresdin USE OF AN OSMOTIC ISOTONIC ELECTROLYTE SOLUTION AS A CELLULAR LIFE MEDIUM IN A COSMETIC, DERMATOLOGICAL OR NUTRITIONAL COMPOSITION

Also Published As

Publication number Publication date
FR3101538A1 (en) 2021-04-09

Similar Documents

Publication Publication Date Title
AR110962A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF HEMOGLOBINOPATHIES
Niego et al. Selective inhibition of brain endothelial Rho-kinase-2 provides optimal protection of an in vitro blood-brain barrier from tissue-type plasminogen activator and plasmin
MA49727B1 (en) Antibodies and polypeptides directed against cd127
TR201903587T4 (en) Compounds for increasing telomerase activity.
MX2021004140A (en) Cells, islets, and organoids that evade immune detection and autoimmunity, methods of production and use thereof.
GB2562406A (en) A method of non destructive monitoring of biological processes in microfluidic tissue culture systems
GB2434157A (en) Platelets from stem cells
MX2007004025A (en) Use of nordihydroguaiaretic acid derivatives in the treatment of drug resistant cancer, viral and microbial infection.
EA201790504A1 (en) MONOLAYER MONONUKLEAR CELLS OF PERIPHERAL BLOOD OR BONE MARROW CELLS AND ITS APPLICATION
EP2029754A4 (en) Magnetosome gene expression in eukaryotic cells
EA201991455A1 (en) COMPOSITIONS AND METHODS FOR TREATING ALPHA-1-ANTITRIPSIN DEFICIENCY
FR3101538B1 (en) Composition of the physiological solution containing sea water and glutamine and usable to increase the functional viability of biological tissues and living cells.
FR3062063B1 (en) MICROBIOTE FECAL FOR TREATING PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT
BR112022018480A2 (en) NLRP3 MODULATORS
EA202191106A1 (en) PROBIOTIC SUPPLEMENT FOR METABOLIC HEALTH CONTAINING LACTOBACILLUS
AU2003271807A8 (en) Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same
Abo Bakr et al. Virulence traits-based behavior of Streptococcus mutans bacteria from dental plaque and dental caries conditions
DE602004005501D1 (en) UNIVERSALLY INSERTABLE VIRUS-INACTIVATED BLOOD PLASMA FROM PARTS OF PLASMA THAT DOES NOT COME FROM WHITE SKULLS
Millan et al. Sostdc1 regulates natural killer cell maturation and cytotoxicity
Kefayat et al. Veillonella parvula: a strictly anaerobic bacterium with high efficacy for safe and specific tumor targeting and colonization
Serafino et al. Thymosin α1 modifies podosome architecture and promptly stimulates the expression of podosomal markers in mature macrophages
Sabbagh et al. Response to:‘response to:‘Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis’ by Sabbagh S et al’by Yang et al
Cortes et al. CML-129: OPTIC Primary Analysis: A Dose-Optimization Study of 3 Starting Doses of Ponatinib (PON)
Pinnaka et al. Marine microbial diversity for sustainable development
Mereuta et al. SURGICAL TREATMENT OF COLORECTAL CANCER WITH LOCAL-REGIONAL EXTENSION

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210409

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5